Agents and Actions

, Volume 36, Issue 3–4, pp C32–C36 | Cite as

Cytokines and platelet-activating factor in human inflamed colonic mucosa

  • D. Rachmilewitz
  • R. Eliakim
  • P. Simon
  • M. Ligumsky
  • F. Karmeli
Experimental Aspects of Gastrointestinal Inflammation New Approaches to Therapy of Gastrointestinal Inflammation General Inflammation Research Topics 3rd Meeting on Side Effects of Anti-Inflammatory Drugs and 13th European Workshop on Inflammation Verona, Italy New Approaches to Therapy of Gastrointestinal Inflammation


Colonic biopsy specimens from patients with active ulcerative colitis and controls were incubated for four hours in the presence or absence of calcium ionophore or antihuman immunoglobulin E (IgE). Platelet-activating factor (PAF) was determined in the tissue by aggregation assay after extraction with 80% ethanol. PAF was not detected in normal mucosa, whereas A23187 and antihuman IgE stimulated its activity: mean ±SE, 43.2±8.6 and 33.0±6.1 pg/10 mg wet weight, respectively. In active ulcerative colitis, A23187 and antihuman IgE induced significantly higher stimulation of PAF synthesis compared to their effects on normal mucosa. The enhanced stimulation of PAF induced by A23187 was dose-dependently inhibited by sulphazalazine, 5-aminosalicylic acid and prednisolone, but not by sulfapyridine. Colonic interleukin-1 content and release during 24 h of culture were significantly higher in patients with active ulcerative colitis and Crohn's disease compared to normal subjects. Prednisolone significantly and dose-dependently inhibited interleukin-1 release. These results suggest that colonic generation of PAF and interleukin-1 are elevated in patients with inflammatory bowel disease and, thus, may have a role in its pathogenesis. Pharmacological suppression of colonic PAF and interleukin-1 production may have beneficial therapeutic effects.


Inflammatory Bowel Disease A23187 Normal Mucosa Calcium Ionophore Aggregation Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. [1]
    J. Benveniste, P. M. Henson and O. G. Cochrane,Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils and a platelet activating factor. J. Exp. Med.136, 1356–1377 (1972).PubMedGoogle Scholar
  2. [2]
    P. M. Henson,Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J. Exp. Med.131, 287–306 (1970).PubMedGoogle Scholar
  3. [3]
    G. Z. Latner, J. M. Lynch, S. J. Betz and P. M. Henson,Human neutrophil-derived platelet activating factor. J. Immunol.124, 676–684 (1980).PubMedGoogle Scholar
  4. [4]
    J. M. Mencia-Huerta and J. Benveniste,Platelet activating factor and macrophages, I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur. J. Immunol.9, 409–415 (1979).PubMedGoogle Scholar
  5. [5]
    J. M. Mencia-Huerta, R. Lewis, E. Razin and K. F. Austen,Antigen-initiated release of platelet activating factor (PAF-acether) from mouse bone-marrow derived mast cells sensitized with monoclonal IgE. J. Immunol.130, 2958–2964 (1983).Google Scholar
  6. [6]
    E. Jouvin-Marche, E. Ninio, G. Beaurain, M. Tence, P. Niaudet and J. Benveniste,Biosynthesis of PAF-acether (platelet activating factor). VII. Precursors of PAF-acether and acetyltransferase activity in human leucocytes. J. Immunol.133, 892–898 (1984).PubMedGoogle Scholar
  7. [7]
    P. M. Henson,Cellular sources of platelet activating factor. InPharmacology of Inflammation and Allergy, vol. 100. (Eds. F. Russo-Marie, B. B. Vorgaftig and J. Benveniste), pp. 63–81, Publications INSERM, Paris 1981.Google Scholar
  8. [8]
    T.-C. Lee, D. J. Lenihan, B. Malone, L. L. Roddy and S. I. Wasserman,Increased biosynthesis of platelet activating factor in activated human eosinophils. J. Biol. Chem.258, 5526–5530 (1984).Google Scholar
  9. [9]
    T. M. McIntyre, G. A. Zimmerman, K. Satoh and S. M. Prescott,Cultured endothelial cells synthesize both platelet activating factor and prostacyclin in response to histamine, bradykinin and adenosine triphosphate. J. Clin. Invest.76, 271–280 (1985).PubMedGoogle Scholar
  10. [10]
    J. Benveniste,Platelet activating factor, a new mediator of anaphylaxis from rabbit and human basophils. Nature249, 581–584 (1974).PubMedGoogle Scholar
  11. [11]
    M. Chignard, J.-P. Le Couedic, M. Tence, B. B. Vargaftig and J. Benveniste,The role of PAF in platelet aggregation. Nature279, 779–880 (1979).Google Scholar
  12. [12]
    J. W. Doebber, M. S. Wu and T. Y. Shen,Platelet activating factor intravenous infusion in rat stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. Biochem. Biophys. Res. Commun.125, 980–987 (1984).PubMedGoogle Scholar
  13. [13]
    D. M. Humphrey, L. M. McManus, K. Satouchi, D. J. Hanahan and R. N. Pinckard,Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab. Invest.46, 422–427 (1982).PubMedGoogle Scholar
  14. [14]
    L. M. McManus, D. J. Hanahan, C. A. Demopoulos and R. N. Pinckard,Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet activating factor (PAF), in the rabbit. J. Immunol.124, 2919–2924 (1980).PubMedGoogle Scholar
  15. [15]
    B. Poitevin, J. M. Mencia-Huerta, R. Roubin and J. Benveniste,Role of PAF acether (platelet activating factor) in neutrophil activation. InThe Pulmonary Circulation and Acute Lung Injury. (Ed. S. I. Said) pp. 357–373, Futura Publishing, Mount Kisso NY, New York 1985.Google Scholar
  16. [16]
    G. Camussi, J. Brentjens, F. Bussolino and C. Tetta,Role of platelet activating factor in immunopathological reactions. InAdvances in Inflammation Research, vol. 11 (Eds. I. Otterness et al.) pp. 92–108. Raven Press, New York 1986.Google Scholar
  17. [17]
    F. Gonzales-Crussi and W. Hseuh,Experimental model of ischemic bowel necrosis. The role of platelet activating factor and endotoxin. Am. J. Pathol.112, 127–135 (1983).PubMedGoogle Scholar
  18. [18]
    A.-C. Rosam, J. L. Wallace and B. J. R. Whittle,Potent ulcerogenic actions of platelet activating factor on the stomach. Nature319, 54–6 (1986).PubMedGoogle Scholar
  19. [19]
    B. J. R. Whittle, T. Morishita, Y. Ohya, F. W. Leung and P. H. Guth,Microvascular actions of platelet activating factor on rat gastric mucosa and submucosa. Am. J. Physiol.251, G772–778 (1986).PubMedGoogle Scholar
  20. [20]
    S. K. Durum, J. A. Schmidt and J. J. Oppenheim,Interleukin 1: An immunological perspective. Ann. Rev. Immunol.3, 263–287 (1985).Google Scholar
  21. [21]
    K. Goto, S. Nakamura, F. Goto and M. Yoshinaga,Generation of interleukin-1-like lymphocyte-stimulating factor at inflammatory sites: Correlation with the infiltration of polymorphonuclear leucocytes. Br. J. Exp. Path.65, 521–532 (1984).Google Scholar
  22. [22]
    C. A. Dinarello,Interleukin 1. Dig. Dis. Sci.33, 255–355 (1988).Google Scholar
  23. [23]
    J. Satsangi, R. A. Wolstencroft, J. Cason, C. C. Ainley, C. C. Dumonde and R. P. H. Thompson,Interleukin 1 in Crohn's disease. Clin. Exp. Immunol.67, 594–605 (1987).PubMedGoogle Scholar
  24. [24]
    P. Sharon, M. Ligumsky, D. Rachmilewitz and U. Zor,Role of prostaglandins in ulcerative colitis. Gastroenterology75, 638–640 (1978).PubMedGoogle Scholar
  25. [25]
    M. Tence, J. Polonsky, J. P. Le Couedic and J. Benveniste,Release, purification, and characterization of platelet activating factor (PAF). Biochimie62, 251–259 (1980).Google Scholar
  26. [26]
    P. L. Simon, J. T. Laydon, J. C. Lee,A modified assay for Interleukin-1 (IL-1). J. Immunol. Meth.84, 85–94 (1985).Google Scholar
  27. [27]
    C. A. Meyers, R. O. Johansen, L. M. Miles et al.Purification and characterization of human recombinant interleukin-1B. J. Biol. Chem.262, 11176–11181 (1987).PubMedGoogle Scholar
  28. [28]
    B. Davis, M. Huffman, R. Knoblock and P. Bader,Logit analysis of interleukin-2 using a BASIC program. Comp. Applicat. Lab.4, 269–275 (1983).Google Scholar
  29. [29]
    R. Roubin and J. Benveniste,Release of lipid mediators from macrophages and its pharmacological modulation. InThe Reticuloendothelial System, vol. 8 (Eds. J. W. Hadden and A. Szentivanyl) pp. 73–96, Plenum New York 1985.Google Scholar
  30. [30]
    D. Rachmilewitz, P. L. Simon, L. W. Schwartz, D. E. Griswold, J. D. Fondacaro and M. A. Wasserman,Inflammatory mediators of experimental colitis in rats. Gastroenterology97, 326–337 (1989).Google Scholar
  31. [31]
    D. Rachmilewitz, P. L. Simon, R. Sjogren, J. D. Fondacaro, M. A. Wasserman and E. Bodecker,Interleukin-1: A sensitive marker of colonic inflammation. Gastroenterology84, A363 (abstract) (1988).Google Scholar
  32. [32]
    D. S. Snyder and E. R. Unanue,Corticosteroids inhibit murine macrophage Ia expression and interleukin-1 production. J. Immunol.129, 1803 (1982).PubMedGoogle Scholar
  33. [33]
    C. A. Dinarello, I. Bishai, L. J. Rosenwasser and F. Coceani,The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activity factor (interleukin-1). Int. J. Immunopharmacol.6, 43 (1984).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1992

Authors and Affiliations

  • D. Rachmilewitz
    • 1
    • 2
  • R. Eliakim
    • 1
    • 2
  • P. Simon
    • 1
    • 2
  • M. Ligumsky
    • 1
    • 2
  • F. Karmeli
    • 1
    • 2
  1. 1.Department of MedicineHadassah University Hospital, Mount ScopusJerusalemIsrael
  2. 2.Department of ImmunologySmith Kline and French LaboratoriesPhiladelphiaUSA

Personalised recommendations